ଶ୍ୱାସକ୍ରିୟା ସିନ୍ସିଟିଆଲ ଭୂତାଣୁ ଟିକା

ଶ୍ୱାସକ୍ରିୟା ସିନ୍ସିଟିଆଲ ଭୂତାଣୁ ଟିକା
Vaccine description
Target disease	RSVPreF3 antigen or subgroup A and B stabilised prefusion F
Type	Protein subunit
Clinical data
Trade names	Arexvy, Abrysvo
Synonyms	GSK3844766A; respiratory syncytial virus vaccine, adjuvanted
data	US DailyMed: syncytial vaccine Respiratory syncytial vaccine;
Routes of; administration	Intramuscular
Legal status
Legal status	US: ℞-only ; EU: Rx-only ;

ଶ୍ୱାସକ୍ରିୟା ସିନ୍ସିଟିଆଲ ଭୂତାଣୁ ଟିକା ( RSV ଟିକା), ଆରେକ୍ସଭି ଏବଂ ଆବ୍ରିସଭୋ ବ୍ରାଣ୍ଡ ନାମରେ ବିକ୍ରି ହୁଏ, ହେଉଛି ଏକ ଟିକା ଯାହା ଶ୍ୱାସକ୍ରିୟା ସିନ୍ସିଟିଆଲ୍ ଭୂତାଣୁ ରୋଗରୁ ରକ୍ଷା କରିଥାଏ ।^[୨] ୬୦ ବର୍ଷରୁ ଅଧିକ ବୟସ୍କଙ୍କଠାରେ ଓ ୨୪ ରୁ ୩୬ ସପ୍ତାହ ଗର୍ଭବତୀ ଥିବା ଶିଶୁର ସୁରକ୍ଷା ପାଇଁ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୧] ବାହୁର ମାଂସପେଶୀରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଏହାକୁ ଏକକ ମାତ୍ରା ଭାବରେ ଦିଆଯାଏ ।^[୨] ^[୧] ଏହି ଟିକା ଦେଲେ ଭୟଙ୍କର ରୋଗ ହେବାର ଆଶଙ୍କା ପ୍ରାୟ ୫୦ରୁ ୮୫% ହ୍ରାସ ହୋଇଥାଏ ।^[୧] ^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଇଞ୍ଜେକ୍ସନ୍, ଥକ୍କା, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।^[୨] ଏଗୁଡ଼ିକ ସାଧାରଣତଃ ଦୁଇ ଦିନ ମଧ୍ୟରେ ସମାଧାନ ହୁଏ ।^[୧] ^[୨] ୨୦୨୩ ମସିହା ସୁଦ୍ଧା ପ୍ରସବ ପୂର୍ବରୁ ଜନ୍ମ ହେବାର ବିପଦ ଉପରେ ପ୍ରଭାବ ଅସ୍ପଷ୍ଟ ଅଛି ।^[୨] ଶରୀରକୁ RSV ରୁ କିପରି ରକ୍ଷା କରାଯିବ ତାହା ପ୍ରତିରକ୍ଷା ପ୍ରଣାଳୀ ଶିକ୍ଷା ଦେଇ ଏହା କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୧] ଆରେକ୍ସଭି ପ୍ରୋଟିନରେ ଆରଏସଭିପ୍ରୀଏଫ୩ (RSVPreF3)ର ଏକ ସଂସ୍କରଣ ଧାରଣ କରିଥିବାବେଳେ ଆବ୍ରିସଭୋରେ ସବ୍ ଗ୍ରୁପ୍ ଏ ଏବଂ ବି ସ୍ଥିର ହୋଇଥିବା ପ୍ରିଫ୍ୟୁଜନ୍ ଏଫ୍ ଅଛି ।^[୧] ^[୨]

୨୦୨୩ ମସିହାରେ ଆମେରିକା, ୟୁରୋପ ଏବଂ କାନାଡ଼ାରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଏହି ଟିକାଗୁଡ଼ିକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା। ^[୫] ^[୯] ^[୧] ^[୨] ^[୧୧] ୨୦୨୩ ସୁଦ୍ଧା ବ୍ୟକ୍ତିଗତ କ୍ରୟ ପାଇଁ ବ୍ରିଟିଶ କଲମ୍ବିଆ, କାନାଡ଼ାରେ ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୨୩୦ ସିଏଡି (CAD) ଭାବରେ ଏହା ଉପଲବ୍‌ଧ ହୋଇଛି ।^[୧୨] ଏହି ଟିକାଗୁଡ଼ିକ ପାଇଁ ଅନୁସନ୍ଧାନ ୧୯୫୦ ଏବଂ ୬୦ ଦଶକରୁ ଚାଲିଆସୁଛି; ୨୦୧୩ରେ ପ୍ରକାଶିତ ଏକ ଅଧ୍ୟୟନ ସହିତ ସାମ୍ପ୍ରତିକ ଟିକାକୁ ଗ୍ରହଣ କରାଯାଇଛି ।^[୧୩] ^[୧୪] ଅନ୍ତର୍ନିହିତ ବିଜ୍ଞାନ କୋଭିଡ଼-୧୯ ଟିକାଗୁଡ଼ିକର ଦ୍ରୁତ ବିକାଶକୁ ସମର୍ଥନ କଲା ।^[୧୩] ^[୧୫]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "Abrysvo". European Medicines Agency (in ଇଂରାଜୀ). 17 July 2023. Archived from the original on 1 October 2023. Retrieved 12 October 2023.
↑ ^୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ "Arexvy EPAR". European Medicines Agency (EMA). 16 June 2023. Archived from the original on 22 August 2023. Retrieved 19 June 2023.
↑ "GSK starts Phase III RSV candidate vaccine programme for older adults". GSK (Press release). 16 February 2021. Archived from the original on 6 May 2023. Retrieved 6 May 2023.
↑ "GSK presents positive clinical data on maternal and older adults RSV candidate vaccines". GSK US (Press release). 21 October 2020. Archived from the original on 25 March 2023. Retrieved 6 May 2023.
↑ ^୫.୦ ^୫.୧ ^୫.୨ "Arexvy- respiratory syncytial visus vaccine recombinant, adjuvanted kit". DailyMed. 3 May 2023. Archived from the original on 22 August 2023. Retrieved 2 June 2023.
↑ ^୬.୦ ^୬.୧ "Arexvy". U.S. Food and Drug Administration (FDA). 3 May 2023. Archived from the original on 22 August 2023. Retrieved 6 May 2023. This article incorporates text from this source, which is in the public domain.
↑ "Arexvy Product Information". Union Register of medicinal products. 9 June 2023. Archived from the original on 22 August 2023. Retrieved 12 June 2023.
↑ "Abrysvo". Union Register of medicinal products. 24 August 2023. Archived from the original on 1 October 2023. Retrieved 2 October 2023.
↑ ^୯.୦ ^୯.୧ "Abrysvo- respiratory syncytial virus vaccine kit". DailyMed. 12 July 2023. Archived from the original on 7 August 2023. Retrieved 6 August 2023.
↑ "Abrysvo". U.S. Food and Drug Administration (FDA). 1 June 2023. Retrieved 2 June 2023.
↑ La Grassa, Jennifer (Aug 4, 2023). "Health Canada approves 1st RSV vaccine for people 60 and older". CBC News. Canadian Broadcasting Corporation. Archived from the original on 13 September 2023. Retrieved 9 September 2023.
↑ "RSV vaccine for older Canadians comes at a cost. Why experts are worried - National | Globalnews.ca". Global News. Archived from the original on 4 October 2023. Retrieved 5 October 2023.
↑ ^୧୩.୦ ^୧୩.୧ "RSV Vaccines Are Nearly Here after Decades of False Starts". Scientific American. 20 March 2023. Archived from the original on 12 April 2023. Retrieved 13 April 2023.
↑ McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD (November 2013). "Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus". Science. 342 (6158): 592–598. Bibcode:2013Sci...342..592M. doi:10.1126/science.1243283. PMC 4461862. PMID 24179220. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
↑ Graham BS (February 2023). "The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design". The New England Journal of Medicine. 388 (7): 579–581. doi:10.1056/NEJMp2216358. PMID 36791157.

[EPAR2023Ab-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ "Abrysvo". European Medicines Agency (in ଇଂରାଜୀ). 17 July 2023. Archived from the original on 1 October 2023. Retrieved 12 October 2023.

[EPAR2023Ar-2] ୨.୦୦ ^୨.୦୧ ^୨.୦୨ ^୨.୦୩ ^୨.୦୪ ^୨.୦୫ ^୨.୦୬ ^୨.୦୭ ^୨.୦୮ ^୨.୦୯ "Arexvy EPAR". European Medicines Agency (EMA). 16 June 2023. Archived from the original on 22 August 2023. Retrieved 19 June 2023.

[3] "GSK starts Phase III RSV candidate vaccine programme for older adults". GSK (Press release). 16 February 2021. Archived from the original on 6 May 2023. Retrieved 6 May 2023.

[4] "GSK presents positive clinical data on maternal and older adults RSV candidate vaccines". GSK US (Press release). 21 October 2020. Archived from the original on 25 March 2023. Retrieved 6 May 2023.

[Daily2023Ar-5] ୫.୦ ^୫.୧ ^୫.୨ "Arexvy- respiratory syncytial visus vaccine recombinant, adjuvanted kit". DailyMed. 3 May 2023. Archived from the original on 22 August 2023. Retrieved 2 June 2023.

[FDA_Arexvy-6] ୬.୦ ^୬.୧ "Arexvy". U.S. Food and Drug Administration (FDA). 3 May 2023. Archived from the original on 22 August 2023. Retrieved 6 May 2023. This article incorporates text from this source, which is in the public domain.

[EU_Arexvy_Product_Information-7] "Arexvy Product Information". Union Register of medicinal products. 9 June 2023. Archived from the original on 22 August 2023. Retrieved 12 June 2023.

[8] "Abrysvo". Union Register of medicinal products. 24 August 2023. Archived from the original on 1 October 2023. Retrieved 2 October 2023.

[Daily2023Ab-9] ୯.୦ ^୯.୧ "Abrysvo- respiratory syncytial virus vaccine kit". DailyMed. 12 July 2023. Archived from the original on 7 August 2023. Retrieved 6 August 2023.

[FDA_Abrysvo-10] "Abrysvo". U.S. Food and Drug Administration (FDA). 1 June 2023. Retrieved 2 June 2023.

[11] La Grassa, Jennifer (Aug 4, 2023). "Health Canada approves 1st RSV vaccine for people 60 and older". CBC News. Canadian Broadcasting Corporation. Archived from the original on 13 September 2023. Retrieved 9 September 2023.

[12] "RSV vaccine for older Canadians comes at a cost. Why experts are worried - National | Globalnews.ca". Global News. Archived from the original on 4 October 2023. Retrieved 5 October 2023.

[SA2023-13] ୧୩.୦ ^୧୩.୧ "RSV Vaccines Are Nearly Here after Decades of False Starts". Scientific American. 20 March 2023. Archived from the original on 12 April 2023. Retrieved 13 April 2023.

[Science2013-14] McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD (November 2013). "Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus". Science. 342 (6158): 592–598. Bibcode:2013Sci...342..592M. doi:10.1126/science.1243283. PMC 4461862. PMID 24179220. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)

[Gra2023-15] Graham BS (February 2023). "The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design". The New England Journal of Medicine. 388 (7): 579–581. doi:10.1056/NEJMp2216358. PMID 36791157.

[୨]

[୧]

[୩]

[୪]

[୫]

[୬]

[୯]

[୧୦]

[୭]

[୮]

[୧୧]

[୧୨]

[୧୩]

[୧୪]

[୧୫]